目的 探讨神经调节蛋白4(Nrg4)对2型糖尿病大鼠心肌细胞凋亡的影响。方法 将SD大鼠分为对照组(Vehicle)、糖尿病组(DM)和Nrg4干预糖尿病组(Nrg4)。实验结束后,取各组大鼠心肌细胞,流式细胞术检测心肌细胞凋亡率,qRT-PCR 检测Bax及Bcl-2的转录表达,Western blot检测凋亡相关蛋白Bax、Bcl-2及Cleaved-caspase 3的表达。结果 与Vehicle组相比,DM组心肌细胞凋亡率明显升高[(35.49±1.37)% vs.(11.98±0.85)%;P＜0.05],促凋亡蛋白Bax与凋亡执行蛋白Cleaved-caspase 3表达明显增多,抗凋亡蛋白Bcl-2表达明显减少,差异有统计学意义(P＜0.05);而Nrg4干预显著抑制糖尿病大鼠心肌细胞凋亡[(19.28±0.96)% vs.(35.49±1.37)%;P＜0.05],降低Bax与Cleaved-caspase 3的表达并促进Bcl-2表达(P＜0.05)。结论 Nrg4干预能缓解2型糖尿病大鼠心肌细胞凋亡。
Abstract
Objective To investigate the effects of neuregulin 4 (Nrg4) on myocardial apoptosis of type 2 diabetic rats. Methods SD rats were randomly divided into vehicle group, diabetes mellites (DM) group and Nrg4 administration group (Nrg4). The apoptosis rate of myocardial cells was detected by flow cytometry, the expression of Bax and Bcl-2 transcription were detected by qRT-PCR, and the expression of apoptosis-related proteins Bax, Bcl-2 and Cleaved caspase 3 were detected by Western blot. Results Compared with the vehicle group, DM significantly promoted cell apoptosis [(35.49±1.37)% vs. (11.98±0.85)%; P＜0.05], heightened Bax and cleaved-caspase 3 expression, and reduced Bcl-2 expression (P＜0.05). While CBD obviously inhibited cell apoptosis [(19.28±0.96)% vs. (35.49±1.37)%; P＜0.05], reduced Bax and cleaved-caspase 3 expression, and increased Bcl-2 expression (P＜0.05). Conclusions Nrg4 attenuates myocardial apoptosis of type 2 diabetic rats.
关键词
神经调节蛋白4 /
2型糖尿病 /
心肌细胞 /
细胞凋亡
Key words
Neuregulin 4 (Nrg4) /
type 2 diabetes /
cardiomyocyte /
cell apoptosis
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Wang L, Cai Y, Jian L, et al. Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy[J]. Cardiovasc Diabetol, 2021,20(1):2.
[2] Seferovic P M, Paulus W J. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes[J]. Eur Heart J, 2015,36(27):1718-1727, 1727a.
[3] Chen Z, Wang G X, Ma S L, et al. Nrg4 promotes fuel oxidation and a healthy adipokine profile to ameliorate diet-induced metabolic disorders[J]. Mol Metab, 2017,6(8):863-872.
[4] Wang G X, Zhao X Y, Meng Z X, et al. The brown fat-enriched secreted factor Nrg4 preserves metabolic homeostasis through attenuation of hepatic lipogenesis[J]. Nat Med, 2014,20 (12): 1436- 1443.
[5] Zhu B, Mei W, Jiao T, et al. Neuregulin 4 alleviates hepatic steatosis via activating AMPK/mTOR-mediated autophagy in aged mice fed a high fat diet[J]. Eur J Pharmacol, 2020,884:173350.
[6] Yan P, Xu Y, Zhang Z, et al. Decreased plasma neuregulin 4 levels are associated with peripheral neuropathy in Chinese patients with newly diagnosed type 2 diabetes: A cross-sectional study[J]. Cytokine, 2019,113:356-364.
[7] Kocak M Z, Aktas G, Atak B M, et al. Is Neuregulin-4 a predictive marker of microvascular complications in type 2 diabetes mellitus?[J]. Eur J Clin Invest, 2020,50(3):e13206.
[8] Yan P, Zhang Z, Miao Y, et al. Changes of circulating neuregulin 4 and its relationship with 25-hydroxy vitamin D and other diabetic vascular complications in patients with diabetic peripheral neuropathy[J]. Diabetol Metab Syndr, 2020,12:42.
[9] Liu M, Xiang G, Lu J, et al. TRAIL protects against endothelium injury in diabetes via Akt-eNOS signaling[J]. Atherosclerosis, 2014,237(2):718-724.
[10] Wang H, Wang L, Hu F, et al. Neuregulin-4 attenuates diabetic cardiomyopathy by regulating autophagy via the AMPK/mTOR signalling pathway[J]. Cardiovasc Diabetol, 2022,21(1):205.
[11] 苏静华,焦 婷,韩 宁,等. 大麻二酚对高糖诱导小鼠肾脏足细胞系MPC5细胞凋亡的保护作用[J]. 武警医学, 2022,33(4):303-306.
[12] 杨文朋,吴方丽,田萧羽,等. 生长分化因子11对炎症微环境中兔BMSCs成骨分化的影响[J]. 北京口腔医学, 2022,30(1):21-24.
[13] 苏静克,苏静华,韩 宁,等. 精脒对老龄小鼠股骨微结构的影响[J]. 武警医学, 2022,33(1):42-45.
[14] 李晓晨. 维格列汀通过miR-21a-5p/PTEN/Akt/mTOR途径提高自噬预防糖尿病心肌病变[D].天津:天津医科大学, 2019.
[15] 游 艳,田萧羽,曾 浪,等. 生长分化因子11对高糖环境中人甲状腺乳头状癌K1细胞凋亡的影响[J]. 武警医学, 2021,32(10):852-855.
[16] Gavaldà N A, Villarroya J, Cereijo R, et al. The endocrine role of brown adipose tissue: an update on actors and actions[J]. Rev Endocr Metab Disord, 2022,23(1):31-41.
[17] Munck T, Boesch M, Verhaegh P, et al. Is there a role for neuregulin 4 in human nonalcoholic fatty liver disease?[J]. PLoS One, 2021,16(5):e251822.
[18] Li M, Chen Y, Jiang J, et al. Elevated serum neuregulin 4 levels in patients with hyperthyroidism[J]. Endocr Connect, 2019,8(6):728-735.
[19] Blüher M. Neuregulin 4: a “hotline” between brown fat and liver[J]. Obesity (Silver Spring), 2019, 27(10): 1555-1557.
[20] Li Y, Jin L, Jiang F, et al. Mutations of NRG4 contribute to the pathogenesis of nonalcoholic fatty liver disease and related metabolic disorders[J]. Diabetes, 2021,70(10):2213-2224.
[21] Yang F, Zhou N, Zhu X, et al. n-3 PUFAs protect against adiposity and fatty liver by promoting browning in postnatally overfed male rats: a role for NRG4[J]. J Nutr Biochem, 2021,93:108628.
[22] Tutunchi H, Mobasseri M, Aghamohammadzadeh N, et al. Serum neuregulin 4 (NRG-4) level and non-alcoholic fatty liver disease (NAFLD): a case-control study[J]. Int J Clin Pract, 2021,75(10):e14555.
[23] Shi J, Xu W, Zheng R, et al. Neuregulin 4 attenuate tubulointerstitial fibrosis and advanced glycosylation end products accumulation in diabetic nephropathy rats via regulating TNF-R1 signaling[J]. Am J Transl Res, 2019,11(9):5501-5513.
[24] Yang Z, Yaling W, Tao L, et al. Cardioprotective effect of NRG-4 gene expression on spontaneous hypertension rats and its mechanism through mediating the activation of ErbB signaling pathway[J]. Cell Mol Biol (Noisy-le-grand), 2022,68(1):89-101.
PDF(1600 KB)
